General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Advanced Non-Small Cell Lung Cancer
Last updated November 23, 2017
Status:
Concluded with an LOI
Manufacturer:
Medexus Pharmaceuticals, Inc.
Indication:
Rheumatic Conditions
Last updated November 20, 2017
Pheburane (sodium phenylbutyrate)
Status:
Concluded with an LOI
Manufacturer:
M�dunik Canada Inc.
Indication:
Urea cycle disorders
Last updated November 20, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Head and Neck Squamous Cell Carcinoma (HNSCC)
Last updated November 20, 2017
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Gastrointestinal Stromal Tumours
Last updated November 9, 2017
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Non-small Cell Lung Cancer
Last updated November 1, 2017
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Non-small Cell Lung Cancer
Last updated November 1, 2017
Status:
Concluded without agreement
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Rheumatoid Arthritis
Last updated October 26, 2017
Status:
Concluded without agreement
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis (CFTR gating mutations)
Last updated October 24, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Primary hyperlipidemia and mixed dyslipidemia
Last updated October 23, 2017